dostęp otwarty

Tom 3, Nr 4 (2018)
Rekomendacje
Opublikowany online: 2019-02-27
Pobierz cytowanie

Wytyczne postępowania w nabytej hemofilii A

Jerzy Windyga, Beata Baran, Edyta Odnoczko, Anna Buczma, Krzysztof Drews, Piotr Laudański, Bronisława Pietrzak, Piotr Sieroszewski
Ginekologia i Perinatologia Praktyczna 2018;3(4):175-188.

dostęp otwarty

Tom 3, Nr 4 (2018)
Rekomendacje
Opublikowany online: 2019-02-27

Streszczenie

Brak

Streszczenie

Brak
Pobierz cytowanie
Informacje o artykule
Tytuł

Wytyczne postępowania w nabytej hemofilii A

Czasopismo

Ginekologia i Perinatologia Praktyczna

Numer

Tom 3, Nr 4 (2018)

Strony

175-188

Data publikacji on-line

2019-02-27

Rekord bibliograficzny

Ginekologia i Perinatologia Praktyczna 2018;3(4):175-188.

Autorzy

Jerzy Windyga
Beata Baran
Edyta Odnoczko
Anna Buczma
Krzysztof Drews
Piotr Laudański
Bronisława Pietrzak
Piotr Sieroszewski

Referencje (51)
  1. Knoebl P, Marco P, Baudo F, et al. EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10(4): 622–631.
  2. W Collins P, Chalmers E, Hart D, et al. United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol. 2013; 162(6): 758–773.
  3. Scandella D, Mattingly M, de Graaf S, et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989; 74(5): 1618–1626.
  4. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010; 148(2): 183–194.
  5. Buczma A, Windyga J. Nabyta hemofilia. Pol. Arch. Med. Wew. 2007; 5(6): 241–245.
  6. Collins P, Macartney N, Davies R, et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004; 124(1): 86–90.
  7. Collins PW, Hirsch S, Baglin TP, et al. UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007; 109(5): 1870–1877.
  8. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981; 45(3): 200–203.
  9. Kessler C, Nemes L. Acquired inhibitors to factor VIII. W: Inhibitors in patients with haemophilia (red. Rodriguez-Merchan E.C. I Lee C.A. Blackwell Science Oxford. ; 2002: 98–114.
  10. Windyga J. Acquired haemophilia. Transf. Med. 2010; 4: 131–132.
  11. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG: An International Journal of Obstetrics and Gynaecology. 2003; 110(3): 311–314.
  12. Tengborn L, Baudo F, Huth-Kühne A, et al. EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012; 119(12): 1529–1537.
  13. Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost. 1995; 73(1): 1–5.
  14. Michiels JJ. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost. 2000; 6(2): 82–86.
  15. DEDEKEN L, ST-LOUIS J, DEMERS C, et al. Postpartum acquired haemophilia: a single centre experience with rituximab. Haemophilia. 2009; 15(5): 1166–1168.
  16. Kasper CK, Pool JG. Letter: Measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh. 1975; 34(3): 875–876.
  17. Odnoczko E, Baran B, Windyga J. Z hemostazą na Ty. BioKsel. 2016.
  18. Windyga J. Diagnostyka laboratoryjna zaburzeń hemostazy. W: Badania laboratoryjne w hematologii. Podręcznik dla słuchaczy studiów medycznych (red. Mariańska B, Fabijańska-Mitek J). Wyd. Lek. PZWL Warszawa. 2003: 192–225.
  19. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia. 2004; 10(2): 169–173.
  20. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002; 8(2): 83–90.
  21. Von Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Med. 2002; 28 Suppl 2: S222–S227.
  22. Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012; 120(1): 39–46.
  23. Zanon E, Pasca S, Santoro C, et al. Activated prothrombin complex concentrate (FEIBA ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry. Br J Haematol. 2018 [Epub ahead of print].
  24. Borg JY, Négrier C, Durieu I, et al. FEIBHAC Study Group. FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry. Haemophilia. 2015; 21(3): 330–337.
  25. Windyga J, Chojnowski K, Klukowska A, et al. Część II: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). Acta Haematologica Polonica. 2017; 48(3): 137–159.
  26. Gringeri A, Fischer K, Karafoulidou A, et al. European Haemophilia Treatment Standardisation Board (EHTSB). Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia. 2011; 17(4): 630–635.
  27. Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017; 92(7): 695–705.
  28. Tarantino MD, Cuker A, Hardesty B, et al. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017; 23(1): 25–32.
  29. Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009; 94(4): 566–575.
  30. Windyga J, Chojnowski K, Klukowska A, et al. W imieniu Grupy Roboczej ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów. Polskie zalecenia postępowania w nabytej hemofilii A. Medycyna Praktyczna. 2011; 10: 1–8.
  31. Windyga J, Stefanska-Windyga E, Odnoczko E, et al. Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors. Haemophilia. 2016; 22(5): e465–e468.
  32. Valentino LA, Holme PA. Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly? Haemophilia. 2015; 21(6): 709–714.
  33. Narodowy Program Leczenia Chorych na Hemofilię i Pokrewne Skazy Krwotoczne. https://www.gov.pl/documents.
  34. Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012; 120(1): 47–55.
  35. Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993; 70(5): 753–757.
  36. Kessler CM, Acs P, Mariani G. Acquired disorders of coagulation: the immune coagulopthies. W: Hemostasis and thrombosis. Basic principles and clinical practice. Fifth edition (red. R. W. Colman, V. J. Marder, A. W. Clowes, J. N. George, S. Z. Goldhaber). Lippincott Williams & Wilkins, Philadelphia, USA. ; 2006: 1061–1084.
  37. GREEN D. The management of acquired haemophilia. Haemophilia. 2006; 12(s5): 32–36.
  38. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121(1): 21–35.
  39. Aggarwal A, Grewal R, Green RJ, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia. 2005; 11(1): 13–19.
  40. D'arena G, Grandone E, Di Minno MND, et al. The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. Blood Transfus. 2016; 14(2): 255–261.
  41. Bonfanti C, Crestani S, Frattini F, et al. Role of rituximab in the treatment of postpartum acquired haemophilia A: a systematic review of the literature. Blood Transfus. 2015; 13(3): 396–400.
  42. Sborov DW, Rodgers GM. How I manage patients with acquired haemophilia A. Br J Haematol. 2013; 161(2): 157–165.
  43. Schulman S, Langevitz P, Livneh A, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost. 1996; 76(3): 344–346.
  44. Lian ECY, Villar MJo, Noy LI, et al. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002; 69(4): 294–295.
  45. Obaji S, Rayment R, Collins P. Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. Haemophilia. 2018; 25(1): e59–e65.
  46. McFadyen JD, Tran H, Kaplan ZS. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol. 2017; 178(6): 986–987.
  47. Nemes L, Pitlik E. Ten years experience with immune tolerance induction therapy in acquired hemophilia. Haematologica. 2003; 88(suppl. 12): 64–68.
  48. Zanon E, Pasca S, Siragusa S, et al. FAIR Study Group. Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. Thromb Res. 2019; 174: 24–26.
  49. Baudo F, de Cataldo F. Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG. 2003; 110(3): 311–314.
  50. Coller BS, Hultin MB, Hoyer LW, et al. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood. 1981; 58(3): 619–624.
  51. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol. 1998; 59(1): 1–4.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl